Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Gilead Sciences Inc. Revenue & Financial Statements
Gilead Sciences Inc. reported revenue of $29.4B for the fiscal year ended December 31, 2025, up 2.4% year over year, with net income of $8.5B and diluted EPS of $6.78.
- Company
- Gilead Sciences Inc. GILD · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 27.3B | 27.3B | 27.1B | 28.8B | 29.4B |
| Cost of revenue | 6.6B | 5.7B | 6.5B | 6.3B | 6.2B |
| Gross profit | 20.7B | 21.6B | 20.6B | 22.5B | 23.2B |
| Operating income | 9.9B | 7.3B | 7.6B | 1.7B | 10.0B |
| Pretax income | (309.0M) | 1.4B | 1.4B | 1.6B | 1.5B |
| Net income | 6.4B | 4.5B | 5.7B | 584.0M | 8.5B |
| Diluted EPS | 4.93 | 3.64 | 4.50 | 0.38 | 6.78 |
| EBITDA | 10.2B | 7.7B | 8.0B | 2.0B | 10.4B |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.7B | 7.0B | 7.5B | 7.6B | 6.7B | 7.1B | 7.8B | 7.9B |
| Cost of revenue | 1.6B | 1.5B | 1.6B | 1.6B | 1.5B | 1.5B | 1.6B | 1.6B |
| Gross profit | 5.1B | 5.4B | 6.0B | 6.0B | 5.1B | 5.6B | 6.2B | 6.3B |
| Operating income | (4.3B) | 2.6B | 888.0M | 2.5B | 2.2B | 2.5B | 3.3B | 2.0B |
| Pretax income | (4.5B) | 2.1B | 956.0M | 2.2B | 1.6B | 2.4B | 3.6B | 2.1B |
| Net income | (4.1B) | 1.6B | 1.2B | 1.8B | 1.3B | 1.9B | 3.1B | 2.2B |
| Diluted EPS | -3.34 | 1.29 | 1.00 | 1.42 | 1.04 | 1.56 | 2.43 | 1.74 |
| EBITDA | (4.2B) | — | 982.0M | 2.5B | 2.3B | 2.6B | 3.4B | 2.1B |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 68.0B | 63.2B | 62.1B | 59.0B | 59.0B |
| Current assets | 14.8B | 14.4B | 16.1B | 19.2B | 18.3B |
| Cash & equivalents | 5.3B | 5.4B | — | — | — |
| Total liabilities | — | — | — | — | — |
| Current liabilities | 11.6B | 11.2B | 11.3B | 12.0B | 11.8B |
| Long-term debt | 25.2B | 23.0B | 23.2B | 24.9B | 22.1B |
| Total debt | 26.7B | 25.2B | 25.0B | 26.7B | 24.9B |
| Stockholders’ equity | 21.1B | 21.2B | 22.8B | 19.3B | 22.7B |
| Net debt | 21.4B | 19.8B | — | — | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 11.4B | 9.1B | 8.0B | 10.8B | 10.0B |
| Investing cash flow | (3.1B) | (2.5B) | (2.3B) | (3.4B) | (4.8B) |
| Financing cash flow | (8.9B) | (6.5B) | (5.1B) | (3.4B) | (7.7B) |
| Capital expenditure | 579.0M | 728.0M | 585.0M | 523.0M | 563.0M |
| Free cash flow | 10.8B | 8.3B | 7.4B | 10.3B | 9.5B |
| Dividends paid | 3.6B | 3.7B | 3.8B | 3.9B | 4.0B |
| Stock-based compensation | 635.0M | 637.0M | 766.0M | 835.0M | 894.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every GILD filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.